Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AVEO PHARMACEUTICALS, INC.

(AVEO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
5.72(c) 5.34(c) 5.46(c) 5.52(c) 5.85(c) Last
317 519 341 239 293 386 185 239 330 230 Volume
-3.38% -6.64% +2.25% +1.10% +5.98% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 47,6 M - -
Net income 2021 -51,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,68x
Yield 2021 -
Sales 2022 129 M - -
Net income 2022 -5,58 M - -
Net Debt 2022 - - -
P/E ratio 2022 -36,0x
Yield 2022 -
Capitalization 201 M 201 M -
Capi. / Sales 2021 4,23x
Capi. / Sales 2022 1,56x
Nbr of Employees 49
Free-Float 99,8%
More Financials
Company
AVEO Pharmaceuticals, Inc. is an oncology biopharmaceutical company that is focused on delivering medicines for patients with cancer. The Company’s products and development program include FOTIVDA, ficlatuzumab, AV-380 and AV-203 AV-203. It develops FOTIVDA in immuno-oncology combinations in refractory renal cell carcinoma (RCC) and other indications and has several other investigational programs in clinical... 
More about the company
Ratings of AVEO Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about AVEO PHARMACEUTICALS, INC.
12/01AVEO Pharmaceuticals Names Jeb Ledell as Operations Chief
MT
12/01AVEO PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
12/01AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
BU
12/01AVEO Oncology Appoints Jeb Ledell as Chief Operating Officer
CI
11/10AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
BU
11/08AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update..
PU
11/08AVEO PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
11/08AVEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/08AVEO : Q3 Earnings Snapshot
AQ
11/08AVEO Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/08Earnings Flash (AVEO) AVEO ONCOLOGY Posts Q3 Revenue $15.2M, vs. Street Est of $13.8M
MT
11/08AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
BU
11/01AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call..
BU
09/20Aveo Oncology Shares Drop 7% After Fast Track Designation for Ficlatuzumab
DJ
09/20AVEO PHARMACEUTICALS' : Head, Neck Cancer Drug Gets FDA Fast-Track Designation
MT
More news
News in other languages on AVEO PHARMACEUTICALS, INC.
11/08Earnings Flash (AVEO) AVEO ONCOLOGY affiche un chiffre d'affaires de 15,2 millions de d..
08/05Earnings Flash (AVEO) AVEO ONCOLOGY annonce un chiffre d'affaires de 7,6 millions de do..
05/10Earnings Flash (AVEO) AVEO ONCOLOGY annonce un chiffre d'affaires de 1,9 million de dol..
03/29Le Fotivda d'AVEO est ajouté aux directives de pratique clinique du National Comprehens..
03/26AVEO Oncology lève 55,2 millions de dollars grâce à l'offre d'actions.
More news
Analyst Recommendations on AVEO PHARMACEUTICALS, INC.
More recommendations
Chart AVEO PHARMACEUTICALS, INC.
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVEO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,85 $
Average target price 19,75 $
Spread / Average Target 238%
EPS Revisions
Managers and Directors
Michael P. Bailey President, Chief Executive Officer & Director
Erick J. Lucera Chief Financial Officer
Kenneth M. Bate Chairman
Matthew Coulter Vice President-Information Technology
Jebediah Ledell Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
AVEO PHARMACEUTICALS, INC.1.39%201
GILEAD SCIENCES, INC.19.65%87 443
BIONTECH SE258.12%70 510
REGENERON PHARMACEUTICALS35.38%68 384
WUXI APPTEC CO., LTD.24.26%64 686
VERTEX PHARMACEUTICALS-12.58%52 531